Indeed, FGF23/FGFR4 signaling is associated with muscle pathogenesis in the heart as well as renal fibrosis (Han et al., 2020; Hao et al., 2021), processes that, if active in skeletal muscle, could explain the decline in muscle quality over time. The gene discussed is FGF23; the disease is renal fibrosis.